Toll Free: 1-888-928-9744

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2016, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 3 molecules, respectively.Cervical Intraepithelial Neoplasia (CIN).

Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Cervical Intraepithelial Neoplasia (CIN) Overview 7 Therapeutics Development 8 Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Overview 8 Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis 9 Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Development by Companies 10 Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Investigation by Universities/Institutes 11 Cervical Intraepithelial Neoplasia (CIN) - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Cervical Intraepithelial Neoplasia (CIN) - Products under Development by Companies 14 Cervical Intraepithelial Neoplasia (CIN) - Products under Investigation by Universities/Institutes 15 Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development 16 CEL-SCI Corp 16 Genexine Inc 17 Inovio Pharmaceuticals Inc 18 PDS Biotechnology Corp 19 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 20 Transgene SA 21 Vaccibody AS 22 Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 ABI-1968 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 aminolevulinic acid hydrochloride - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 DNA Vaccine to Target E7 for HPV Associated Cancers - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 GLBL-101c - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 GX-188E - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Leukocyte Interleukin - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 PDS-0101 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 TG-4001 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 VB-1016 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 VGX-3100 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects 60 Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products 61 Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones 62 Featured News & Press Releases 62 Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed 62 Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016 62 Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as "Best Therapeutic Vaccine" by World Vaccine Congress 63 Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet 63 Apr 23, 2015: Global clinical development accelerated as cervical intraepithelial neoplasia therapeutic, GX-188E received expanded approval for Phase II from Europe 65 Mar 02, 2015: Genexines cervical intraepithelial neoplasia therapeutic "GX-188E" receives approval for Phase II in Europe 65 Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 66 Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology 67 Oct 10, 2012: Inovio Pharma's DNA-based Therapeutic Cancer Vaccine Produces Immune Responses To Kill Target Cells In Phase I Study 68 May 01, 2012: Inovio Receives US Patent Protection For Synthetic Vaccine For Cervical Dysplasia And Cancer 69 Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines 70 Oct 05, 2011: Inovio's Synthetic Vaccine For Cancer Recognized As Most Promising Research At Global Vaccine Congress 71 Jul 15, 2011: Inovio Demonstrates T Cell Immune Response From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 71 May 09, 2011: Inovio Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 72 Appendix 74 Methodology 74 Coverage 74 Secondary Research 74 Primary Research 74 Expert Panel Validation 74 Contact Us 74 Disclaimer 75
List of Tables
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2016 8 Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corp, H2 2016 16 Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine Inc, H2 2016 17 Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 18 Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corp, H2 2016 19 Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2016 20 Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, H2 2016 21 Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H2 2016 22 Assessment by Monotherapy Products, H2 2016 23 Number of Products by Stage and Target, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H2 2016 60 Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H2 2016 61



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify